TY - JOUR
T1 - Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
AU - Hertz, Daniel L.
AU - Tofthagen, Cindy
AU - Rossi, Emanuela
AU - Bernasconi, Davide Paolo
AU - Lim, Jiyoon
AU - Carlson, Martha
AU - Sheffield, Katharine E.
AU - Nekhlyudov, Larissa
AU - Grech, Lisa
AU - Von Ah, Diane
AU - Mayo, Samantha J.
AU - Ruddy, Kathryn J.
AU - Chan, Alexandre
AU - Alberti, Paola
AU - Lustberg, Maryam B.
AU - Tanay, Mary
N1 - Funding Information:
We would like to thank all survey respondents and organizations who helped with survey distribution, including Bowel Cancer UK and Myeloma UK. P.A. is supported by Bicocca Starting Grant (University of Milano-Bicocca).
Funding Information:
We would like to thank all survey respondents and organizations who helped with survey distribution, including Bowel Cancer UK and Myeloma UK. P.A. is supported by Bicocca Starting Grant (University of Milano-Bicocca).
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2024/1
Y1 - 2024/1
N2 - Purpose: Clinical practice guidelines recommend altering neurotoxic chemotherapy treatment in patients experiencing intolerable chemotherapy-induced peripheral neuropathy (CIPN). The primary objective of this survey was to understand patient’s perspectives on altering neurotoxic chemotherapy treatment, including their perceptions of the benefits of preventing irreversible CIPN and the risks of reducing treatment efficacy. Methods: A cross-sectional online survey was distributed via social networks to patients who were currently receiving or had previously received neurotoxic chemotherapy for cancer. Survey results were analyzed using descriptive statistics and qualitative analysis. Results: Following data cleaning, 447 participants were included in the analysis. The median age was 57 years, 93% were white, and most were from the UK (53%) or USA (38%). Most participants who were currently or recently treated expected some CIPN symptom resolution (86%), but 45% of those who had completed treatment more than a year ago reported experiencing no symptom resolution. Participants reported that they would discontinue chemotherapy treatment for less severe CIPN if they knew their symptoms would be permanent than if symptoms would disappear after treatment. Most patients stated that the decision to alter chemotherapy or not was usually made collaboratively between the patient and their treating clinician (61%). The most common reason participants were reluctant to talk with their clinician about CIPN was fear that treatment would be altered. Participants noted a need for improved understanding of CIPN symptoms and their permanence, better patient education relating to CIPN prior to and after treatment, and greater clinician understanding and empathy around CIPN. Conclusions: This survey highlights the importance of shared decision-making, including a consideration of both the long-term benefits and risks of altering neurotoxic chemotherapy treatment due to CIPN. Additional work is needed to develop decision aids and other communication tools that can be used to improve shared decision making and help patients with cancer achieve their treatment goals.
AB - Purpose: Clinical practice guidelines recommend altering neurotoxic chemotherapy treatment in patients experiencing intolerable chemotherapy-induced peripheral neuropathy (CIPN). The primary objective of this survey was to understand patient’s perspectives on altering neurotoxic chemotherapy treatment, including their perceptions of the benefits of preventing irreversible CIPN and the risks of reducing treatment efficacy. Methods: A cross-sectional online survey was distributed via social networks to patients who were currently receiving or had previously received neurotoxic chemotherapy for cancer. Survey results were analyzed using descriptive statistics and qualitative analysis. Results: Following data cleaning, 447 participants were included in the analysis. The median age was 57 years, 93% were white, and most were from the UK (53%) or USA (38%). Most participants who were currently or recently treated expected some CIPN symptom resolution (86%), but 45% of those who had completed treatment more than a year ago reported experiencing no symptom resolution. Participants reported that they would discontinue chemotherapy treatment for less severe CIPN if they knew their symptoms would be permanent than if symptoms would disappear after treatment. Most patients stated that the decision to alter chemotherapy or not was usually made collaboratively between the patient and their treating clinician (61%). The most common reason participants were reluctant to talk with their clinician about CIPN was fear that treatment would be altered. Participants noted a need for improved understanding of CIPN symptoms and their permanence, better patient education relating to CIPN prior to and after treatment, and greater clinician understanding and empathy around CIPN. Conclusions: This survey highlights the importance of shared decision-making, including a consideration of both the long-term benefits and risks of altering neurotoxic chemotherapy treatment due to CIPN. Additional work is needed to develop decision aids and other communication tools that can be used to improve shared decision making and help patients with cancer achieve their treatment goals.
KW - Cancer
KW - Chemotherapy-induced peripheral neuropathy
KW - Neurotoxic chemotherapy
KW - Patient preferences, survey
KW - Treatment alteration
UR - http://www.scopus.com/inward/record.url?scp=85180511611&partnerID=8YFLogxK
U2 - 10.1007/s00520-023-08209-0
DO - 10.1007/s00520-023-08209-0
M3 - Article
C2 - 38129602
AN - SCOPUS:85180511611
SN - 0941-4355
VL - 32
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 1
M1 - 48
ER -